Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat +/- Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
NCT04175912Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2020
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pevonedistat in intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Started Mar 2020; status: active, not recruiting.
02
Drugs
pevonedistat
03
Conditions
intrahepatic cholangiocarcinoma (ICC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04175912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04175912.